261 related articles for article (PubMed ID: 17943421)
1. Development of a human physiologically based pharmacokinetic (PBPK) model for inorganic arsenic and its mono- and di-methylated metabolites.
El-Masri HA; Kenyon EM
J Pharmacokinet Pharmacodyn; 2008 Feb; 35(1):31-68. PubMed ID: 17943421
[TBL] [Abstract][Full Text] [Related]
2. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in mice following acute oral administration of arsenate.
Kenyon EM; Del Razo LM; Hughes MF
Toxicol Sci; 2005 May; 85(1):468-75. PubMed ID: 15703264
[TBL] [Abstract][Full Text] [Related]
3. Using mathematical modeling to infer the valence state of arsenicals in tissues: A PBPK model for dimethylarsinic acid (DMA
Bilinsky LM; Thomas DJ; Fisher JW
J Theor Biol; 2019 Jan; 461():215-229. PubMed ID: 30393109
[TBL] [Abstract][Full Text] [Related]
4. Trivalent arsenicals are bound to proteins during reductive methylation.
Naranmandura H; Suzuki N; Suzuki KT
Chem Res Toxicol; 2006 Aug; 19(8):1010-8. PubMed ID: 16918239
[TBL] [Abstract][Full Text] [Related]
5. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in C57BL6 mice following subchronic exposure to arsenate in drinking water.
Kenyon EM; Hughes MF; Adair BM; Highfill JH; Crecelius EA; Clewell HJ; Yager JW
Toxicol Appl Pharmacol; 2008 Nov; 232(3):448-55. PubMed ID: 18706920
[TBL] [Abstract][Full Text] [Related]
6. A review of the enzymology of arsenic metabolism and a new potential role of hydrogen peroxide in the detoxication of the trivalent arsenic species.
Aposhian HV; Zakharyan RA; Avram MD; Sampayo-Reyes A; Wollenberg ML
Toxicol Appl Pharmacol; 2004 Aug; 198(3):327-35. PubMed ID: 15276412
[TBL] [Abstract][Full Text] [Related]
7. Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment.
Cohen SM; Arnold LL; Eldan M; Lewis AS; Beck BD
Crit Rev Toxicol; 2006 Feb; 36(2):99-133. PubMed ID: 16736939
[TBL] [Abstract][Full Text] [Related]
8. Intracellular interaction and metabolic fate of arsenite and arsenate in mice and rabbits.
Vahter M; Marafante E
Chem Biol Interact; 1983 Oct; 47(1):29-44. PubMed ID: 6640784
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man.
Buchet JP; Lauwerys R; Roels H
Int Arch Occup Environ Health; 1981; 48(1):71-9. PubMed ID: 6894292
[TBL] [Abstract][Full Text] [Related]
10. Role of the alkali labile sites, reactive oxygen species and antioxidants in DNA damage induced by methylated trivalent metabolites of inorganic arsenic.
Soto-Reyes E; Del Razo LM; Valverde M; Rojas E
Biometals; 2005 Oct; 18(5):493-506. PubMed ID: 16333750
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a Physiologically Based Pharmacokinetic (PBPK) Model for Inorganic Arsenic Exposure Using Data from Two Diverse Human Populations.
El-Masri HA; Hong T; Henning C; Mendez W; Hudgens EE; Thomas DJ; Lee JS
Environ Health Perspect; 2018 Jul; 126(7):077004. PubMed ID: 30024383
[TBL] [Abstract][Full Text] [Related]
12. Species variations in the biliary and urinary excretion of arsenate, arsenite and their metabolites.
Csanaky I; Gregus Z
Comp Biochem Physiol C Toxicol Pharmacol; 2002 Mar; 131(3):355-65. PubMed ID: 11912060
[TBL] [Abstract][Full Text] [Related]
13. Biokinetics and subchronic toxic effects of oral arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid in v-Ha-ras transgenic (Tg.AC) mice.
Xie Y; Trouba KJ; Liu J; Waalkes MP; Germolec DR
Environ Health Perspect; 2004 Aug; 112(12):1255-63. PubMed ID: 15345372
[TBL] [Abstract][Full Text] [Related]
14. Study of factors influencing the in vivo methylation of inorganic arsenic in rats.
Buchet JP; Lauwerys R
Toxicol Appl Pharmacol; 1987 Oct; 91(1):65-74. PubMed ID: 3672518
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic modeling of arsenic in the mouse.
Gentry PR; Covington TR; Mann S; Shipp AM; Yager JW; Clewell HJ
J Toxicol Environ Health A; 2004 Jan; 67(1):43-71. PubMed ID: 14668111
[TBL] [Abstract][Full Text] [Related]
16. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Wang Z; Zhou J; Lu X; Gong Z; Le XC
Chem Res Toxicol; 2004 Jan; 17(1):95-103. PubMed ID: 14727923
[TBL] [Abstract][Full Text] [Related]
17. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes.
Petrick JS; Ayala-Fierro F; Cullen WR; Carter DE; Vasken Aposhian H
Toxicol Appl Pharmacol; 2000 Mar; 163(2):203-7. PubMed ID: 10698679
[TBL] [Abstract][Full Text] [Related]
18. Accumulation and metabolism of arsenic in mice after repeated oral administration of arsenate.
Hughes MF; Kenyon EM; Edwards BC; Mitchell CT; Razo LM; Thomas DJ
Toxicol Appl Pharmacol; 2003 Sep; 191(3):202-10. PubMed ID: 13678653
[TBL] [Abstract][Full Text] [Related]
19. Association of plasma folate, vitamin B12 levels, and arsenic methylation capacity with developmental delay in preschool children in Taiwan.
Lin YC; Chung CJ; Huang YL; Hsieh RL; Huang PT; Wu MY; Ao PL; Shiue HS; Huang SR; Su CT; Lin MI; Mu SC; Hsueh YM
Arch Toxicol; 2019 Sep; 93(9):2535-2544. PubMed ID: 31473767
[TBL] [Abstract][Full Text] [Related]
20. Effect of selenite on the disposition of arsenate and arsenite in rats.
Csanaky I; Gregus Z
Toxicology; 2003 Apr; 186(1-2):33-50. PubMed ID: 12604169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
